Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $17,735,022.90. This represents a 3.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Jim Wassil also recently made the following trade(s):
- On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00.
- On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00.
Vaxcyte Price Performance
PCVX opened at $86.51 on Wednesday. The stock’s 50 day moving average price is $87.46 and its 200-day moving average price is $94.42. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06.
Hedge Funds Weigh In On Vaxcyte
Hedge funds and other institutional investors have recently modified their holdings of the stock. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter valued at approximately $27,000. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Meeder Asset Management Inc. grew its stake in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares during the period. Nomura Asset Management Co. Ltd. bought a new position in Vaxcyte in the third quarter worth $92,000. Finally, Signaturefd LLC lifted its position in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after buying an additional 358 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $145.71.
Check Out Our Latest Stock Analysis on PCVX
Vaxcyte Company Profile
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
- Five stocks we like better than Vaxcyte
- How is Compound Interest Calculated?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- What Are Treasury Bonds?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What is a SEC Filing?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.